Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) posted its quarterly earnings results on Monday. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03, FiscalAI reports. Perspective Therapeutics had a negative return on equity of 44.22% and a negative net margin of 28,467.97%.The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.09 million.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $3.23 on Wednesday. The business has a 50-day moving average of $3.09 and a 200-day moving average of $3.94. Perspective Therapeutics has a 1 year low of $1.96 and a 1 year high of $6.16.

Analyst Ratings Changes

A number of research analysts have commented on the company. Piper Sandler decreased their price objective on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating on the stock in a report on Tuesday. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a research note on Friday, July 24th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $12.38.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Deutsche Bank AG grew its position in shares of Perspective Therapeutics by 6.1% during the 4th quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock valued at $149,000 after acquiring an additional 3,119 shares during the period. Vontobel Holding Ltd. grew its holdings in Perspective Therapeutics by 25.0% during the fourth quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock valued at $69,000 after purchasing an additional 5,000 shares during the period. Russell Investments Group Ltd. increased its position in Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock worth $29,000 after buying an additional 5,475 shares during the last quarter. Barclays PLC raised its stake in shares of Perspective Therapeutics by 10.7% in the fourth quarter. Barclays PLC now owns 92,791 shares of the company’s stock valued at $255,000 after buying an additional 8,936 shares during the period. Finally, Aigen Investment Management LP purchased a new position in shares of Perspective Therapeutics during the 4th quarter valued at $28,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.